Preliminary results of a phase II trial on solid tumors of detorubicin, a new anthracyclin.

Abstract

A phase II trial of detorubicin (DTR) has been conducted on 164 patinets with solid tumors. Regressions greater than or equal to 50% were obtained in 23% of breast carcinoma patients, in 17% of head and neck carcinoma patients and of melanoma patients, and in 6% of ureri cervic carcinoma patients. DTR seems as toxic as adriamycin on bone marrow and the heart and might induce a little less alopecia.

• Journal: Cancer clinical trials (Cancer Clin Trials) Vol. 3 Issue 2 Pg. 115-20 ( 1980) ISSN: 0190-1206 [Print] United States
• PMID: 7428135 (Publication Type: Journal Article)

Chemical References

• Antineoplastic Agents
• detorubicin
• Daunorubicin

Topics

• Adolescent
• Adult
• Aged
• Antineoplastic Agents (adverse effects, therapeutic use)
• Breast Neoplasms (drug therapy)
• Carcinoma (drug therapy)
• Daunorubicin (analogs & derivatives, therapeutic use, toxicity)
• Dose-Response Relationship, Drug
• Drug Evaluation
• Female
• Head and Neck Neoplasms (drug therapy)
• Humans
• Male
• Melanoma (drug therapy)
• Middle Aged
• Neoplasms (drug therapy)
• Uterine Neoplasms (drug therapy)